Shilajit Research

How shilajit is studied

Different study designs answer different questions. Knowing which kind of study sits behind a claim is the fastest way to judge it.

See human vs animal evidence and cellular and gene-expression research for how these play out in shilajit specifically.

Research quality, explained

Study design is only the first filter. Formal grading approaches such as GRADE ask how certain we can be about an effect, which depends on risk of bias, consistency between studies, directness, precision and the chance of unpublished negative results.^[1] We apply the same thinking in plain language:

• Was there a fair comparison?Randomisation and a placebo group protect against wishful interpretation.
• Was it big enough?Small trials produce unstable results that often shrink when repeated.
• Did it measure something that matters?A blood marker is less meaningful than symptoms, function or health events.
• Has anyone else found the same thing?Independent replication is the strongest single upgrade a finding can get.
• Who paid, and who supplied the product?Not disqualifying, but it raises the bar for replication.

A useful illustration comes from the shilajit literature itself. A 2011 review noted that in vivo work on shilajit’s antioxidant activity had used an irrelevant dose and no positive control, and concluded that its bioactivity lacked substantial evidence.^[2] The review’s authors weren’t rejecting shilajit; they were pointing out that the studies weren’t yet good enough to support the claims.

How to read a shilajit study

You don’t need statistical training to judge most shilajit papers. Work through these questions using the abstract and methods section.

1. What exactly was tested?A named, standardised extract, a raw resin or a multi-ingredient product? Results belong to that preparation. Why preparation and dose matter
2. Who took part?Age, sex, health status and country. A result in men aged 45–55 tells you little about women or younger men.
3. What was it compared with?Placebo, another treatment or nothing at all?
4. How many people, for how long?Dozens for weeks is a pilot-sized study. Sample size
5. What was measured?Was the headline outcome chosen before the study began, or picked from many measurements afterwards?
6. How big was the effect?“Statistically significant” means unlikely to be chance alone, not large or important. Statistical significance
7. Who funded it?Check the funding and conflict-of-interest statements at the end of the paper. Who funds shilajit research

The long version, with an annotated example, is how to read a shilajit study.

Why one preparation isn’t every product

Shilajit is not a standard chemical, and the research reflects that. Several of the human trials cited across this site, on testosterone, exercise, skin and bone, used the same branded, standardised aqueous extract.^[3][4][5][6] Another used a “processed” shilajit capsule,^[7] and a trial in women used 200 mg shilajit tablets twice daily.^[8]

A resin from a different region, purified differently and taken at an approximate “pea-sized” dose, is a different intervention. That doesn’t mean it can’t work. It means the existing trials can’t be used to say it does. See why research on one preparation may not apply to another and standardised and branded extracts.

Why one study doesn’t prove a claim

The best-known shilajit trial randomised 75 healthy men to a purified extract or placebo for 90 days and reported higher testosterone in the shilajit group.^[3] It is a properly designed study and worth taking seriously. It is also one trial, in one age group, of one product. Until independent groups repeat it in other populations, the right summary is “one trial found”, not “shilajit boosts testosterone”. See why one study doesn’t prove a health claim.

Funding and conflicts of interest

Public funding for supplement trials is limited, so ingredient suppliers often fund or supply the product for trials. This is normal and disclosed in good journals. It matters most when nearly all the evidence for an ingredient comes from studies of one supplier’s product, because the incentive to publish positive results, and to frame results positively, is concentrated in one place. Independent replication is the remedy. See who funds shilajit research.

What hasn’t been studied

The gaps are as informative as the findings. As far as we can tell, there are no published controlled trials on any of the following:

• Long-term useNothing beyond about a year of daily use.
• Pregnancy, breastfeeding and under-18sNo safety data at all.
• Medicine interactionsNo formal interaction studies.
• Raw resin products as sold in the UKTrials mostly used standardised extracts.
• Head-to-head preparationsNo trials comparing different shilajit products or doses directly.
• Everyday claimsSleep, mood, energy and immunity in people.

We keep a running list on evidence gaps and record every new paper in the new studies log.

How we grade evidence

Every topic on our evidence pages carries a rating on a six-point scale, from “not studied” to “strong”. The rating reflects study type, size, controls and replication.

• StrongConsistent results across several well-designed human trials. No shilajit topic is here.
• LimitedOne or two small controlled human trials. Shilajit’s best-studied topics sit here.
• Preclinical onlyAnimal or laboratory research only.

The full scale is explained on our evidence rating system and how we grade evidence, with a reader’s guide on how to use an evidence rating.